argument we need more, not fewer, new drugs.
Perhaps this relative paucity reflects the limitations of our old methods for drug discovery. However, the relative paucity of solutions demands new solutions and new technologies, not a retreat.
During the last 20 years new indications have emerged for older drugs, for example ACE inhibitors in acute myocardial infarction and (with indapamide) in prevention of secondary stroke, aldosterone antagonists and beta blockers to reduce mortality in heart failure, and the use of antibiotics to treat peptic ulcer.
When a drug is first developed its ultimate indications (and degree of innovation) may not be recognised. At the same time, we have seen, frighteningly rapidly, the emergence of antibacterial, antimalarial and antiviral drug resistance, making some old drugs progressively less effective.
The need for new drugs is obvious -for old and new infections, as well as for the chronic diseases mentioned by Burnet -and there is enormous potential for the development of new drugs.
According to the WHO Report on Genomics and World Health:
It has been estimated that successful drug therapy currently is directed at fewer than 500 targets.
Considering that the human genome contains some 30 000 genes, it is possible that its study could lead to at least 3000 to 5000 potential new targets for therapy.
Currently, predominant candidates include G proteincoupled receptor families and other receptors and related molecules, a wide range of enzymes including proteases, kinases and phosphatases, hormones, growth factors, chemokines, soluble receptors and related molecules, and many others. Exactly the same principles are being applied to the search for agents to interfere with key biochemical pathways in pathogens, based on information which is being obtained from the pathogen genome project. 4 Just as discoveries in the old disciplines of chemistry and biochemistry in the early 20th century took many years to translate into new drugs, so it will take time to learn how to realise the potential of the new discipline of genomics. But learn we must.
If a potential drug discovery/innovation/invention is not patented, it will never find its way into practice. With new drugs said to cost around $1 billion to bring to market, investment will only be made if patent protection is assured. If the degree of 'real innovation' must be predetermined, based on previous experience, valuable therapies may be lost. Whatever our differences of emphasis, the ultimate goal is the same: effective, accessible, affordable medicines for all.
Quality use of medicines -prescribing for manufacturers or patients?
Editor, -I refer to the editorial 'Quality use of generic medicines' (Aust Prescr 2004;27:80-1).
Confusion resulting from the availability of multi-sourced brands of medications is predictable within our rapidly changing prescribing and dispensing environments. In contrast to troglitazone, which was withdrawn because of rare but fatal liver failure, placebo-controlled trials show that the risk of liver function abnormalities (reversible elevations of alanine transferase greater than three times the upper limit of normal) in patients treated with pioglitazone or rosiglitazone is 0.2-0.3% and not different from placebotreated patients. 1 While rare case reports of hepatocellular injury and hepatic failure have been described in patients treated with these newer drugs 2 , whether liver dysfunction can be definitively attributed to the thiazolidinedione has been challenged. 3 As Mr Grubb acknowledges, liver function may be abnormal in patients with diabetes and/or obesity, particularly due to non-alcoholic fatty liver disease.
Furthermore, liver function may actually improve following treatment with these drugs, due to a reduction in hepatic lipid content. 4 As stated in our article, and the accompanying 
Warfarin: balancing the benefits and harms
Editor, -As an eye surgeon I was surprised to read that warfarin was contraindicated when eye surgery was Only three complaints were made by healthcare professionals.
Most of the complaints were made by companies about their rivals' promotional materials. These promotional materials have to be withdrawn if they are in breach of the Code, however by the time a complaint is resolved the advertising campaigns may have concluded.
There seems to be a growing concern about the promotion of prescription medicines to the general public. Several complaints involved the connection between companies' products and the information on web sites about related topics.
There was also a complaint about a television advertisement, but this was not upheld. More details about the complaints can be found in the annual report. 3 
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